Prix Poniard Pharmaceuticals Inc (PARD)

Poniard Pharmaceuticals, Inc. is a bio-pharmaceutical company, which focuses on the development and commercialization of oncology products. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2011-12-30. The firm focuses on the development and commercialization of oncology products to impact the lives of people with cancer. The company develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The firm has offices in San Francisco, California; and Seattle, Washington in United States.